FDA granted accelerated approval to Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
FDA approved Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
FDA granted first marketing clearance for RefleXion Medical’s SCINTIX biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers.
FLAG-003, an investigational small molecule therapy developed by FLAG Therapeutics Inc. for the treatment of diffuse intrinsic pontine glioma—a rare, highly aggressive and difficult to treat brain tumor found in children—has been granted Rare Pediatric Disease designation from FDA.
The National Cancer Institute approved the following clinical research studies last month.
For a decade, thousands of PhDs in epigenetics may have been relying on the wrong tool as they study the biological processes that regulate how and when genes are expressed or silenced.
It took a team of researchers more than 18 months to get their paper on epigenetic variation published—likely because they are saying that epigeneticists have been fishing in the wrong pond for a decade.
As members of the 118th Congress returned to Washington this week, everyone is focused on raising the nation’s debt limit, especially following Treasury Secretary Jane Yellen’s announcement that her agency would begin taking extraordinary measures to prevent the government from triggering a default.Â
Jeffrey Holzbeierlein, the William L. Valk endowed professor and chair of urology at the University of Kansas Medical Center, was named physician in chief of The University of Kansas Cancer Center.
Richard D. Carvajal, a clinician and researcher in melanoma and early phase drug development, was named deputy physician-in-chief and director of medical oncology at the Northwell Health Cancer Institute.
